Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy

analysed using ICP OES was within the limits suggested by the manufacturer
(As, Cu, Ni 98% without purification
were used. The labelling efficiency of 90 Y DOTATATE after SepPak purification
was 0.79% ± 0.58%.
A case study was conducted by V. Artiko, Institute of Nuclear Medicine,
Clinical Centre of Serbia, Belgrade (Serbia), on a patient affected by characinoid
metastases in the liver.
Therapy was carried out with 2.0–4.5 GBq of 90 Y DOTATATE per patient,
in one cycle, with slow infusion in saline (150 mL/15 min), which lasted 4 h.
Mixed amino acids (arginine and lysine) were infused to the patients 30 min
prior to therapy. Whole body bremsstrahlung imaging collected 24 h after
90 Y DOTATATE administration, and SPECT imaging with 111 In pentetreotide and
99m Tc tin colloid were performed using a dual head gamma camera, as shown in
Fig. 10.13.
In a few areas where there was impairment of liver uptake of 99m Tc tin
colloids (greater in the lateral and medial part of the right upper lobe and less
in the lower edge of the left lobe), there was an increased accumulation of
111 In pentetreotide and the therapeutic radiopharmaceutical 90 Y DOTATATE that
bind to somatostatin receptors.
(a) Tc-99m tin colloid (b) In-111 pentetreotide (c) Y-90 DOTATATE
FIG. 10.13. SPECT imaging (a and b) and whole body bremsstrahlung imaging (c).
197